Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile of VCaP_ctrl and VCaP_enz stimulated by DHT and enzalutamide

ABSTRACT: Gene expression profile of VCaP_ctrl and VCaP_enz stimulated by DHT and enzalutamide

PROVIDER: PRJNA577856 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10291955_1.fastq.gz	Fastqsanger.gz
	SRR10291955_2.fastq.gz	Fastqsanger.gz
	SRR10291956_1.fastq.gz	Fastqsanger.gz
	SRR10291956_2.fastq.gz	Fastqsanger.gz
	SRR10291957_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

Gene expression profile of VCaP_ctrl and VCaP_enz stimulated by DHT and enzalutamide

Project description:VCaP_ctrl (Vc) and VCaP_enz (Ver) cells were starved for 2 days and stimulated with 1 nM DHT or 1 μM enzalutamide or both treatment. Gene expression profiles were examined to distinguish the difference of Vc and Ver.

2022-10-01 | GSE138939 | GEO

Expression data from LNCaP cells treated with DHT and enzalutamide

Project description:Enzalutamide (formerly MDV3100 and available commercially as Xtandi), a novel androgen receptor (AR) signaling inhibitor, blocks the growth of castration-resistant prostate cancer (CRPC) in cellular model systems and was shown in a clinical study to increase survival in patients with metastatic CRPC. Enzalutamide inhibits multiple steps of AR signaling: (1) binding of androgens to AR, (2) AR nuclear translocation, and (3) association of AR with DNA. Here we used Affymetrix human genome microarray technology to investigate the global programme of gene expression of LNCaP cells in response to enzalutamide alone and in the context of DHT-stimulated androgen receptor gene expression. LNCaP cells were grown in RPMI 1640 supplemented with 5% hormone depleted FBS and treated with vehicle (control sample) , DHT (100 nM), enzalutamide (1 or 10 M-BM-5M) or DHT (100 nM) plus enzalutamide (1 or 10 M-BM-5M)for 16 hours for RNA extraction and hybridization. Each condition was done in triplicate.

2013-04-01 | E-GEOD-44905 | biostudies-arrayexpress

Expression data from LNCaP cells treated with DHT and enzalutamide

2013-04-01 | GSE44905 | GEO

RNA sequencing of LNCaP cells treated with castration and/or enzalutamide

Project description:The goal of this study was to determine how androgen receptor inhibition alters transcriptional programs in prostate cancer cells. LNCaP prostate cancer cells were grown in 10% charcoal-stripped serum (CSS) supplemented with 0.5 nanomolar dihydrotestosterone (DHT), in CSS without DHT modeling castration, with CSS + DHT but in the presence of 10 micromolar enzalutamide, or in CSS without DHT (castrated) and in the presence of enzalutamide for 72 hours. Analysis shows that androgen receptor target genes are reduced with castration, enzalutamide or the combination of castration + enzalutamide.

2022-05-12 | GSE202755 | GEO

Gene expression profile of VCaP_ctrl and VCaP_enz stimulated by DHT and enzalutamide

Project description:Gene expression profile of VCaP_ctrl and VCaP_enz stimulated by DHT and enzalutamide

| OEX00002013 | NODE

Contribution of BET proteins to androgen (DHT)-stimulated gene expression program

Project description:Competitive inhibitors of acetyl-lysine binding to the bromodomains of the BET (bromodomain and extra terminal) family are being developed for the treatment of solid and heme malignancies. BET family member BRD4 function at enhancers/super-enhancers has been shown to sustain signal-dependent or pathogenic gene expression programs. Here we tested the hypothesis that the transcription factor drivers of castration-resistant prostate cancer (CRPC) clinical progression, including the Androgen Receptor (AR), are critically dependent on BRD4 and thus represent a sensitive solid tumor indication for the BET inhibitor ABBV-075. DHT-stimulated transcription of AR target genes was inhibited by ABBV-075 without significant effect on AR protein expression. Further, ABBV-075 disrupted DHT-stimulated recruitment of BET family member BRD4 to gene regulatory regions co-occupied by AR, including the well-established PSA and TMPRSS2 enhancers. Persistent BET inhibition disrupted the composition and function of AR occupied enhancers as measured by a reduction in AR and H3K27Ac ChIP signal and inhibition of eRNA transcription. ABBV-075 displayed potent anti-proliferative activity in multiple models of resistance to second generation anti-androgens and inhibited the activity of AR-V7 and the AR LBD gain-of-function mutations, F877L and L702H. ABBV-075 was also a potent inhibitor of MYC and the TMPRSS2-ETS fusion protein, important parallel transcription factor drivers of CRPC.

2017-02-21 | GSE86245 | GEO

Gene expression profile of LAPC4 stimulated by 5α-Abi

Project description:LAPC4 cells were starved for 2 days and stimulated with 1µM 5α-Abi or 0.1nM DHT. Gene expression profiles are detected to determine the effect of 5a-Abi on prostate cancer cell line.

2016-03-01 | GSE75387 | GEO

Gene expression profile of LAPC4 stimulated by 5Î±-Abi

Project description:LAPC4 cells were starved for 2 days and stimulated with 1ÂµM 5Î±-Abi or 0.1nM DHT. Gene expression profiles are detected to determine the effect of 5a-Abi on prostate cancer cell line. LAPC4 cells were starved for 2 days with phenol red-free and serum free-medium and stimulated with 1ÂµM 5Î±-Abi or 0.1nM DHT for 48h. Gene expression profiles are detected to determine the effect of 5a-Abi on prostate cancer cell line.

2016-03-01 | E-GEOD-75387 | biostudies-arrayexpress

Expression profile of 22Rv1 cells upon DHT treatment

Project description:To determine genes regulated by Androgen Receptor in response to DHT treatment in 22Rv1, we cultured 22Rv1 cells in full serum containing media and then added DHT for 24 hrs. RNA was harvested after 24 hrs of treatment and gene expression profiling was performed by RNA-Seq

2017-11-01 | GSE86503 | GEO

Gene expression profile of control and enzalutamide-resistant C4-2 PCa cell line

Project description:We report the expression profile of genes in control and enzalutamide drug-resistant (C4-2-ENZ) C4-2 cells. The C4-2-ENZ cells were treated with enzalutmaide for at least 1 months. C4-2-CON serves as a control. Total RNA was extracted for RNA-seq.

2022-12-01 | GSE189966 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data